tradingkey.logo

MaxCyte Inc

MXCT
0.808USD
0.0000.00%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
86.17MMarktkapitalisierung
VerlustKGV TTM

MaxCyte Inc

0.808
0.0000.00%

mehr Informationen über MaxCyte Inc Unternehmen

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

MaxCyte Inc Informationen

BörsenkürzelMXCT
Name des UnternehmensMaxCyte Inc
IPO-datumMar 29, 2016
CEOMasoud (Maher)
Anzahl der mitarbeiter114
WertpapierartOrdinary Share
GeschäftsjahresendeMar 29
Addresse9713 Key West Avenue,
StadtROCKVILLE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20850
Telefon13015175556
Websitehttps://www.maxcyte.com/
BörsenkürzelMXCT
IPO-datumMar 29, 2016
CEOMasoud (Maher)

Führungskräfte von MaxCyte Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+100000.00%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+80000.00%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75000.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+29210.00%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+29210.00%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
+50000.00%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
+18526.00%
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Sandoval
Mr. David Sandoval
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+100000.00%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+80000.00%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75000.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+29210.00%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+29210.00%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
+50000.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product sales
3.95M
57.89%
Product
3.95M
57.89%
Licenses
2.23M
32.60%
other
650.00K
9.52%
Nach RegionUSD
Name
Umsatz
Anteil
Inside the United States
3.84M
56.17%
Outside the United States
2.99M
43.83%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product sales
3.95M
57.89%
Product
3.95M
57.89%
Licenses
2.23M
32.60%
other
650.00K
9.52%

Aktionärsstatistik

Aktualisiert: Sat, Feb 7
Aktualisiert: Sat, Feb 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Cadian Capital Management LP
7.71%
Capricorn Fund Managers Ltd
7.69%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.19%
Andere
64.18%
Aktionäre
Aktionäre
Anteil
Cadian Capital Management LP
7.71%
Capricorn Fund Managers Ltd
7.69%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.19%
Andere
64.18%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
29.83%
Investment Advisor/Hedge Fund
24.34%
Hedge Fund
17.87%
Research Firm
4.86%
Private Equity
4.73%
Individual Investor
1.74%
Venture Capital
0.36%
Bank and Trust
0.19%
Pension Fund
0.15%
Andere
15.93%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
282
79.67M
74.69%
-13.89M
2025Q3
287
82.96M
77.85%
-17.02M
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Cadian Capital Management LP
8.23M
7.71%
-686.87K
-7.71%
Sep 30, 2025
Mirabella Financial Services LLP
8.20M
7.69%
+1.60M
+24.24%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.04M
7.54%
-168.77K
-2.06%
Sep 30, 2025
The Vanguard Group, Inc.
5.59M
5.24%
-13.59K
-0.24%
Sep 30, 2025
River Global Investors LLP
5.50M
5.15%
+2.24M
+68.99%
Oct 23, 2025
Vitruvian Partners LLP
5.04M
4.73%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
4.25M
3.98%
+12.10K
+0.29%
Sep 30, 2025
Mudita Advisors LLP
3.37M
3.16%
--
--
Sep 30, 2025
AXA Investment Managers UK Ltd.
2.77M
2.6%
+571.18K
+25.93%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.6%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.6%
iShares Micro-Cap ETF
Anteil0.03%
Invesco Nasdaq Biotechnology ETF
Anteil0.02%
Avantis US Small Cap Equity ETF
Anteil0.02%
ProShares Ultra Nasdaq Biotechnology
Anteil0.02%
iShares Russell 2000 Value ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
iShares Russell 2000 ETF
Anteil0.01%
Global X Russell 2000 ETF
Anteil0.01%
iShares Biotechnology ETF
Anteil0.01%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI